Bristol investigation expands
Executive Summary
Investigation of Bristol-Myers Squibb by the New Jersey U.S. Attorney "has expanded to include a review of whether there was any violation of Federal securities laws in connection with the proposed settlement with Apotex" under the terms of a 2004 consent order with the Securities & Exchange Commission, the company says in its third quarter earnings release Oct. 26. The U.S. Attorney is investigating governance issues relating to the company's negotiations with Apotex; Bristol's failed settlement with Apotex over generic Plavix may impact the company's compliance with a deferred prosecution agreement with the New Jersey U.S. Attorney. The Department of Justice is also conducting a criminal investigation of the proposed settlement (1"The Pink Sheet" Aug. 14, 2006, p. 3)...
You may also be interested in...
Bristol May Be An Acquisition Target Following Entry Of Plavix Generics
The entry of generic competition for Bristol-Myers Squibb/Sanofi-Aventis' blockbuster antithrombotic Plavix could make Bristol an acquisition target
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.